1Kirwan JR.The synovium in rheumatoid arthritis: evidence for (at least) two pathologies. Arthritis Rheum,2004,50:1-4.
2Khanna D, McMahon M, Furst DE.Safety of tumour necrosis factor-alpha antagonists.Drug Saf,2004,27:307-324.
3Taylor PC.Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Curr Pharm Des,2003,9:1095-1106.
4Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum,2003,48:1521-1529.
同被引文献24
1Michou L, Lasbleiz S, Rat AC, et al. Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gent and a human autoimmunity gene[J]. Proc Natl Acad Sci U S A,2007,104(5) :1649 -1654.
2Johansson M,Arlestig L, Hallmans C, et al. PTPN22 polymorphism and anti - cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease [ J ]. Arthritis Res Ther, 2006,8 (1):19.
3Kang CP, Lee HS, Ju H,et al. A functional haplotype of the PADI4 gene associated with increased rheumatoid arthritis susceptibility in Koreans [ J ]. Arthritis Rheum,2006,54 ( 1 ) :90 - 96.
4Bokarewa M, Tarkowski A, Magnusson M. Pathological survivin expression links viral infections with pathogenesis of erosive rheumatoid arthritis [ J ]. Scand J Immunol,2007,66 ( 2 - 3 ) : 192 - 198.
5Firestein GS. hnmunologic mechanisms in the Pathogenesis of rheumatoid arthritis [ J ]. J Clin Rheumatol,2005,11 ( 3 Suppl ) :39.
6Oliver JE, Silman AJ. Risk factors for the development of rheumatoid arthritis [ J 1. Scand J Rheumatol,2006,35 (3) : 169 - 174.
7Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis[ J]. Rheumatology ( oxford ) ,2003,42 ( Suppl 2):11 -16.
8Melnnes IB, Leung BP, Liew FY. Cell - cell interactions in synovitis. Interactions between T lymphocytes and synovial cells [J]. Arthritis Res,2000,2 (5) :374 - 378.
